IL13 and Alzheimer disease: PAC-14028 also alleviated dermatitis-associated damages in the oxazolone-induced AD-like murine model, including reducing IL-4 and IL-13 signaling through STAT-3 and STAT-6 and TRPV1 expression [88,89], aligning with observations of its trial in human AD [145].